Search results for: 'changes profitability study'

Frost & Sullivan has recently completed a comprehensive analysis on the current and future strategic imperatives of game-changing Asia-Pacific (APAC) pharmaceutical companies. The analysis primarily focuses on the changing trends in the pharmaceutical industry with respect to drug research and development, manufacturing, supply chain, and marketing...

The research service primarily focuses on the changing trends in the pharmaceutical industry with respect to drug research and development, manufacturing, supply chain, and marketing. The study provides key insights into the transforming pharmaceutical value chain, with the adoption of technology and shift towards digitalization of key processes ac...

The report provides an overview of the global vaccine market estimating the market size broken down by different segments. Vaccines, though a sub-set of biologics, have a completely different dynamic. Not only are they largely designed for a healthy cohort but are also exponentially influenced by government actions and policies. While old generatio...

This market insight discusses the rheumatoid arthritis pharmaceutical drugs currently in the global market as well as those in the development stage. It offers a competitive analysis of the drugs and a forecast of their impact on the market. Drugs in the development stage are segmented by clinical trial phase as well as by drug class. The study cov...

The IVD market constantly changing. Mega Trends such as consolidation, automation, and reimbursement policies affect every aspect of the market. This study looks at the effects of these trends on three global consumer segments: hospitals, laboratories, and patients. The growing importance of diagnostics in patient care is expanding beyond hospitals...

The healthcare landscape is experiencing a profound shift as it shifts away from traditional fee-for-service models toward value-based care. This transition emphasizes collaboration among healthcare stakeholders, fostering a patient-centric approach. The focus is not merely on the quantity of services delivered but also on the quality of care, enco...

The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...

The digital health industry has maintained a consistent growth trajectory. Investing in technologies that help organizations achieve the quintuple aim of healthcare is a constant priority. However, high inflation and tight monetary policy will impact the investment landscape as it shifts from top-line growth to profitability. The use of AI tech...

he global life science industry is in a state of flux. While the recent years have seen the advent of multiple novel technologies, such as in-vitro diagnostics (IVD), CRISPR-Cas9, virtual clinical trials, and liquid biopsy, the industry stands at a crossroad with challenges in scaling-up and commercializing such technologies. In addition, companies...